Neurocrine
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
CEOKyle W. Gano
CEOKyle W. Gano
Employees1,800
Employees1,800
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded1992
Founded1992
Employees1,800
Employees1,800
NBIX Key Statistics
Market cap12.77B
Market cap12.77B
Price-Earnings ratio43.78
Price-Earnings ratio43.78
Dividend yield—
Dividend yield—
Average volume895.12K
Average volume895.12K
High today$131.00
High today$131.00
Low today$128.51
Low today$128.51
Open price$129.94
Open price$129.94
Volume381.26K
Volume381.26K
52 Week high$157.98
52 Week high$157.98
52 Week low$84.23
52 Week low$84.23
NBIX News
TipRanks 6d
Neurocrine initiates Phase 1 study of NBIP-01435Neurocrine (NBIX) Biosciences announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, pharma...
Analyst ratings
85%
of 27 ratingsBuy
85.2%
Hold
14.8%
Sell
0%
People also own
Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.